z0n0p schreef:
Of zoals Kruimer in juni zei:
"Two words about Quinvaxem.
We introduced this product in 2006. We sold 6.3 million doses and we’re the only competitor at that time with Glaxo having the major share of the market. The market increased very rapidly in the next couple of years and in the tender period, which goes to three years from 2007 to 2009 we were awarded $0.5 billion worth of contracts by the United – by UNICEF and the Pan American Health Organization. At price of 360 per dose, that translates into a large number of doses and you work out the numbers, last year we sold just shy of 40 million doses and this year we should see a significant uptick in the volume and the revenue that is derived from this product.
The next tender period, which is from 2010 to 2012, we have submitted the bid for, the outcome of that bid is confidential and won't be known until the fourth quarter. But we’re very confidential – very confident that due to our low cost, our impeccable service record, 100% reliability of supply and the fact that at this moment we own 50% of the world market for this, with Glaxo being number two. We held a very strong position.
In the meantime there are two other Indian manufacturers that have qualified. India wrote our a tender very recently with a very short time period to submit and basically I think it’s a clever way to keep the Indian market to the Indian suppliers, which in a way is good for us because that draws away the excess capacity from Indian suppliers towards the Indian market. That market there is 50 million doses per year and the western – the other market is about 150 million. So at this moment in 2008 (red: moet zijn 2009!) only about half of the market demand that UNICEF has forecasting has been fulfilled".